Top

CNS Drugs

Published in:

01-03-2005 | Review Article

Prevention of Schizophrenia

Can it Be Achieved?

Authors: Cheng Lee, Professor Thomas H. McGlashan, Scott W. Woods

Published in: CNS Drugs | Issue 3/2005

Abstract

Schizophrenia is a serious mental disorder with a profound impact on patients, their caregivers and society. It is also an expensive disorder to treat, despite being relatively rare. In this paper, prevention of schizophrenia is described in terms of primary, secondary and tertiary prevention. Schizophrenia is regarded as a neurodevelopmental disorder with different phases. Primary prevention essentially involves education programmes about the association of obstetric complications and the increased risk of schizophrenia. Secondary prevention involves intervention at the prodromal phase. We review the literature and discuss the evidence relating to intervention in this phase of the illness. Early intervention could result in reduction in morbidity and better quality of life for the patients and their families. The prodromal phase can now be identified, based on current symptoms, with reliability and predictive validity for the risk of development of schizophrenia in the following year. We also discuss possible risks faced by prodromal patients, such as unnecessary stigmatisation, and the role of drug treatment during intervention at this stage. Any recommendation that antipsychotic medications be routinely prescribed in this phase should be supported by more research work. Drug and psychosocial intervention is indicated as part of tertiary prevention to prevent further disability in the illness.

Warner R, de Girolamo G. Epidemiology of mental disorders and psychosocial problems: schizophrenia. Geneva: World Health Organization, 1995

Aleman A, Kahn RS, Selten J-P. Sex differences in the risk of schizophrenia: evidence from meta-analysis. Arch Gen Psychiatry 2003; 60(6): 565–71PubMedCrossRef

Hafner H, Maurer K, Loffler W, et al. The epidemiology of early schizophrenia: influence of age and gender on onset and early course. Br J Psychiatry 1994; 164 Suppl. 23: 29–38

Loranger AW. Sex differences in age of onset of schizophrenia. Arch Gen Psychiatry 1984; 41: 157–61PubMedCrossRef

Frangou S, Murray RM. Schizophrenia. London: Martin Dunitz, 1996

Kupfer DJ, Sartorius N. The usefulness and use of second-generation antipsychotic medications [abstract]. Curr Opin Psychiatry 2002; 15 Suppl. 1: S17

Rice DP, Miller LS. The economics burden of schizophrenia: conceptual and methodology issues and cost estimates. In: Moscarelli M, Rupp A, Sartorius N, editors. Handbook of mental health economics and health policy. Vol. 1: schizophrenia. New York: John Wiley and Sons, 1996: 321–34

Caplan G. Principles of preventive psychiatry. New York: Basic Books, 1964

Mrazek PJ, Haggerty RJ, editors. Reducing risks for mental disorders: frontiers for preventive intervention research. Washington, DC: National Academy Press, 1994

10.

Zubin J, Spring B. Vulnerability: a new view of schizophrenia. J Abnorm Psychol 1977; 86: 103–26PubMedCrossRef

11.

Kestenbaum CJ. Children at risk from schizophrenia. Am J Psychother 1980; 34(2): 164–77PubMed

12.

Gottesman II, Shields J. Schizophrenia and genetics: a twin study vantage point. New York: Academic Press, 1972

13.

Gottesman II. Schizophrenia genesis: the origin of madness. New York: WH Freeman and Company, 1991

14.

Kendler KS, McGuire M, Gruenberg AM, et al. Clinical heterogeneity in schizophrenia and the pattern of psychopathology in relatives: results from an epidemiologically based family study. Acta Psychiatr Scand 1994; 89: 294–300PubMedCrossRef

15.

Sham PC, Jones P, Russell A, et al. Age at onset, sex, and familial psychiatric morbidity in schizophrenia: Camberwell Collaborative Psychosis Study. Br J Psychiatry 1994; 165: 466–73PubMedCrossRef

16.

Murray RM, Lewis SW, Reveley AM. Towards an aetiological classification of schizophrenia. Lancet 1985; 8436: 1023–6CrossRef

17.

Murray RM, Lewis SW. Is schizophrenia a neurodevelopmental disorder? BMJ 1987; 295: 681–2PubMedCrossRef

18.

Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987; 44(7): 660–9PubMedCrossRef

19.

Weinberger DR. From neuropathology to neurodevelopment. Lancet 1995; 346: 552–7PubMedCrossRef

20.

Weinberger DR. Schizophrenia as a neurodevelopmental disorder. In: Hirsch SR, Weinberger DR, editors. Schizophrenia. London: Blackwood, 1995: 295–323

21.

McClure RK, Weinberger DR. The neurodevelopmental hypothesis of schizophrenia: a review of the evidence. In: Breier A, Tran PV, Herrea JM, et al., editors. Current issues in the psychopharmacology of schizophrenia. Philadelphia (PA): Lippincott Williams & Wilkins, 2001: 27–56

22.

Hollister JM, Laing P, Mednick SA. Rhesus incompatibility as a risk factor for schizophrenia in male adults. Arch Gen Psychiatry 1996; 53: 19–24PubMedCrossRef

23.

Kendall RE, Juszczak E, Cole SK. Obstetrical complications and schizophrenia: a case control study based on standardized obstetrical records. Br J Psychiatry 1996; 168: 556–61CrossRef

24.

Jones PB, Rantakallio PR, Hartikainen AL, et al. Schizophrenia as a long term outcome of pregnancy, delivery and perinatal complications: a 28 year follow-up of the 1966 North Finland general population birth cohort. Am J Psychiatry 1998; 155(3): 355–64PubMed

25.

Dalman C, Alleback PA, Cullberg J, et al. Obstetrical complications and the risk of schizophrenia. Arch Gen Psychiatry 1999; 56: 234–40PubMedCrossRef

26.

Susser E, Neugebauer R, Heok HW. Schizophrenia after perinatal famine: further evidence. Arch Gen Psychiatry 1996; 53: 25–31PubMedCrossRef

27.

Brown AS, Schaefer CA, Wyatt RJ, et al. Maternal exposure to respiratory infections and adult schizophrenia spectrum disorders: a prospective birth cohort study. Schizophr Bull 2000; 26(2): 287–95PubMedCrossRef

28.

Mednick S, Machon RA, Huttunen MO. Adult schizophrenia following prenatal exposure to an influenza epidemic. Arch Gen Psychiatry 1988; 45: 189–92PubMedCrossRef

29.

O’Callaghan E, Sham P, Takei N, et al. Schizophrenia after prenatal exposure to 1957 A2 influenza epidemic. Lancet 1991; 337: 1248–50PubMedCrossRef

30.

Sham P, O’Callaghan E, Takei N, et al. Schizophrenia following prenatal exposure to influenza epidemics between 1939–1960. Br J Psychiatry 1992; 160: 461–6PubMedCrossRef

31.

O’Reilly RL. Viruses and schizophrenia. Aust N Z J Psychiatry 1994; 28(2): 222–8PubMedCrossRef

32.

McGrath J, Murray RM. Risk factors for schizophrenia: from conception to birth. In: Hirsch SR, Weinberger DR, editors. Schizophrenia. Oxford: Blackwell Science, 1995: 187–205

33.

Cutting J. The psychology of schizophrenia. Edinburgh: Churchill Livingstone, 1985

34.

O’Callaghan E, Larkin C, Kinsella A, et al. Familial, obstetric, and other clinical correlates of minor physical anomalies in schizophrenia. Am J Psychiatry 1991; 148: 479–83PubMed

35.

Green MF, Bracha HS, Satz P, et al. Preliminary evidence for an association between minor physical anomalies and second trimester neurodevelopment in schizophrenia. Psychiatry Res 1994; 53(2): 119–27PubMedCrossRef

36.

McGrath J, van Os J, Hoyos C, et al. Minor physical anomalies in the functional psychosis: associations with clinical and putative aetiological variables. Schizophr Res 1995; 18: 9–20PubMedCrossRef

37.

Davis JO, Bracha HS. Prenatal growth markers in schizophrenia: a monozygotic co-twin control study. Am J Psychiatry 1996; 153(9): 1166–72PubMed

38.

Fananas L, van Os J, Murray RM. Dermatoglyphic a-b ridge count as a possible marker for developmental insult in schizophrenia: replication in two samples. Schizophr Res 1996; 20: 307–14PubMedCrossRef

39.

Jones PB, Rogers B, Murray RM, et al. Childhood development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet 1994; 334: 1398–402CrossRef

40.

Jones PB, Done DJ. From birth to onset: a developmental perspective of schizophrenia in two national birth cohorts. In: Keshavan MS, Murray RM, editors. Neurodevelopment and adult psychopathology. Cambridge: Cambridge University Press, 1997: 119–36

41.

Done DJ, Crow TJ, Johnstone EC, et al. Childhood antecedents of schizophrenia and affective illness. BMJ 1994; 309: 699–703PubMedCrossRef

42.

Chua SE, Murray RM. The neurodevelopmental theory of schizophrenia: evidence concerning structure and neuropsychology. Acta Neuropsychiatrica 1996; 8(2): 25–34

43.

Davies N, Russell A, Jones PB, et al. What characteristics of schizophrenia predate psychosis? J Psychiatr Res 1997; 32(3–4): 121–31

44.

Delisi LE, Hoff AL, Schwartz JE. Brain morphology in first episode schizophrenic-like psychotic patients: a quantitative magnetic resonance imaging study. Biol Psychiatry 1991; 129: 159–75CrossRef

45.

Degreef G, Ashtari M, Bogerts B, et al. Volumes of ventricular system subdivisions measured from magnetic resonance images in first-episode schizophrenic patients. Arch Gen Psychiatry 1992; 49: 531–7PubMedCrossRef

46.

Woodruff PWR, Murray RM. The aetiology of brain abnormalities in schizophrenia. In: Ancill R, editor. Schizophrenia: exploring the spectrum of psychosis. Chichester: John Wiley, 1994: 95–144

47.

Chua SE, McKenna PJ. Schizophrenia: a brain disease? A critical review of structural and functional cerebral abnormality in the disorder. Br J Psychiatry 1995; 166: 563–82PubMedCrossRef

48.

Lawrie SM, Abukmeil SS. Brain abnormality in schizophrenia: a systematic review of volumetric magnetic resonance imaging studies. Br J Psychiatry 1998; 172: 110–20PubMedCrossRef

49.

Harrison PJ. The neuropathology of schizophrenia: a critical review of the data and their interpretation. Brain 1999; 122: 593–624PubMedCrossRef

50.

Zipursky RB, Lim KO, Sullivan EV, et al. Widespread cerebral gray matter volume deficits in schizophrenia. Arch Gen Psychiatry 1992; 49(3): 195–205PubMedCrossRef

51.

Harvey I, Ron MA, Du Boulay G, et al. Reduction of cortical volume in schizophrenia on magnetic resonance imaging. Psychol Med 1993; 23(3): 591–604PubMedCrossRef

52.

Lim K, Tew W, Koshner M, et al. Cortical grey matter volume deficit is present in first episode schizophrenia. Schizophr Res 1995; 15: 95–6CrossRef

53.

Pieri J, Gupta BK, Bagwell W, et al. MRI abnormalities in first episode schizophrenia: association in neurological impairment [abstract]. Schizophr Res 1995; 15: 90CrossRef

54.

Lim KO, Sullivan EV, Zipursky RB, et al. Cortical gray matter volume deficits in schizophrenia: a replication. Schizophr Res 1996; 20: 157–64PubMedCrossRef

55.

Wright IC, Ellison ZR, Sharma T, et al. Mapping of grey matter changes in schizophrenia. Schizophr Res 1999; 35: 1–14PubMedCrossRef

56.

Weinberger DR, DeLisi LE, Perman G, et al. Computed tomography scans in schizophreniform disorder and other acute psychiatric patients. Arch Gen Psychiatry 1982; 39: 778–83PubMedCrossRef

57.

Weinberger DR, Bigelow LB, Kleinman JE, et al. Cerebral ventricular enlargement in chronic schizophrenia: association with poor response to treatment. Arch Gen Psychiatry 1980; 37: 11–4PubMedCrossRef

58.

Nasrallah HA, Olson SC, McCalley WM, et al. Cerebral ventricular enlargement in schizophrenia: a preliminary follow-up study. Arch Gen Psychiatry 1986; 43(2): 157–9PubMedCrossRef

59.

Illowsky B, Juliano DM, Bigelow LB, et al. Stability of CT scan findings in schizophrenia. J Neurol Neurosurg Psychiatry 1988; 51: 209–13PubMedCrossRef

60.

Vita A, Sacchetti E, Valvassori G, et al. Brain morphology in schizophrenia. Acta Psychiatr Scand 1988; 78: 618–21PubMedCrossRef

61.

Jaskiw GE, Juliano DM, Goldberg TE, et al. Cerebral ventricular enlargement in schizophreniform disorder does not progress: a seven year follow-up study. Schizophr Res 1994; 14: 23–8PubMedCrossRef

62.

Marsh L, Suddath RL, Higgins N, et al. Medial temporal lobe structures in schizophrenia: relationship of size to duration of illness. Schizophr Res 1994; 11(3): 225–38PubMedCrossRef

63.

Vita A, Dieci M, Giobbio GM, et al. Time course of cerebral ventricular enlargement in schizophrenia supports the hypothesis of its neurodevelopmental nature. Schizophr Res 1997; 23: 25–30PubMedCrossRef

64.

Mathalon DH, Sullivan EV, Lim KO, et al. Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study. Arch Gen Psychiatry 2001; 58(2): 148–57PubMedCrossRef

65.

Thompson PM, Vidal C, Giedd JN, et al. Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. Proc Natl Acad Sci U S A 2001; 98(20): 11650–5PubMedCrossRef

66.

Wood SJ, Velakoulis D, Smith DJ, et al. A longitudinal study of hippocampal volume in first episode psychosis and chronic schizophrenia. Schizophr Res 2001; 52(1–2): 37–46PubMedCrossRef

67.

Hass GL, Sweeney JA. Premorbid and onset features of first-episode schizophrenia. Schizophr Bull 1992; 18(3): 373–86CrossRef

68.

Keshavan MS, Schooler NR. First-episode studies in schizophrenia: criteria and characterization. Schizophr Bull 1992; 18(3): 491–513PubMedCrossRef

69.

Loebel AD, Lieberman JA, Alvir JM, et al. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992; 149(9): 1183–8PubMed

70.

Beiser M, Erikson D, Fleming JAE, et al. Establishing the onset of psychotic illness. Am J Psychiatry 1993; 150: 1349–54PubMed

71.

Olin SC, Mednick SA. Risk factors of psychosis: identifying vulnerable populations premorbidly. Schizophr Bull 1996; 22: 223–40PubMedCrossRef

72.

Hafner H, Maurer K, Loffler W, et al. The influence of age and sex on the onset and early course of schizophrenia. Br J Psychiatry 1993; 162: 80–6PubMedCrossRef

73.

Jones P, Bebbington P, Foerster A, et al. Premorbid social underachievement in schizophrenia: results from the Camberwell Collaborative Psychosis Study. Br J Psychiatry 1993; 162: 65–71PubMedCrossRef

74.

Yung AR, McGorry PD. The initial prodrome in psychosis: descriptive and qualitative aspects. Aust N Z J Psychiatry 1996; 30: 587–99PubMedCrossRef

75.

Yung AR, McGorry PD. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull 1996; 22: 353–70PubMedCrossRef

76.

Woods SW, Miller T, McGlashan TH. The ‘prodromal’ patient: both symptomatic and at-risk. CNS Spectrum 2001; 6(3): 223–32

77.

National Early Psychosis Project Clinical Guidelines Working Party. Australian clinical guidelines for early psychosis: National Early Psychosis Project. Melbourne: University of Melbourne, 1998

78.

Birchwood M, Todd P, Jackson C. Early intervention in psychosis: the critical period hypothesis. Br J Psychiatry Suppl 1998; 172(33): 53–9PubMed

79.

Geddes JR, Lawrie SM. Obstetric complications and schizophrenia. Br J Psychiatry 1995; 167: 786–93PubMedCrossRef

80.

Kelly RH, Danielsen BH, Golding JM, et al. Adequacy of prenatal care among women with psychiatric diagnoses giving birth in California in 1994 and 1995. Psychiatr Serv 1999; 50: 1584–90PubMed

81.

Warner R. The prevention of schizophrenia: what interventions are safe and effective? Schizophr Bull 2001; 27(4): 551–62PubMedCrossRef

82.

Davidson M, Reichenberg A, Rabinowitz J, et al. Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. Am J Psychiatry 1999; 156: 1328–35PubMed

83.

Jablensky A. Schizophrenia: the epidemiological horizon. In: Hirsch SR, Weinberger DR, editors. Schizophrenia. Oxford: Blackwell Science, 1995: 206–52

84.

Comblatt BA, Keilp JG. Impaired attention, genetics, and the pathophysiology of schizophrenia. Schizophr Bull 1994; 20: 31–46CrossRef

85.

Cornblatt BA, Obuchowski M. Attention and clinical symptoms in schizophrenia. Psychiatr Q 1997; 58: 655–60

86.

Cornblatt BA. Predictors of schizophrenia and preventive intervention. In: Breier A, Tran PV, Herrea JM, et al., editors. Current issues in the psychopharmacology of schizophrenia. Philadelphia (PA): Lippincott Williams & Wilkins, 2001: 389–406

87.

Cornblatt BA, Obuchowski M, Roberts S, et al. Cognitive and behavioral precursors of schizophrenia. Dev Psychopathol 1999; 11: 487–508PubMedCrossRef

88.

DSM-III-R. Diagnostic and statistical manual of mental disorders. 3rd rev. ed. Washington, DC: American Psychiatric Association, 1987

89.

DSM-IV. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994

90.

Jackson HJ, McGorry PD, McKenzie D. The reliability of DSM-III prodromal symptoms in first-episode psychotic patients. Acta Psychiatr Scand 1994; 90: 375–8PubMedCrossRef

91.

Jackson HJ, McGorry PD, Dudgeon P. Prodromal symptoms of schizophrenia in first-episode psychosis: prevalence and specificity. Compr Psychiatry 1995; 36: 241–50PubMedCrossRef

92.

Hafner H, Riecher-Rossler A, Hambrect M, et al. IRAOS: an instrument for the assessment of onset and early course of schizophrenia. Schizophr Bull 1992; 6: 209–23

93.

Herz MI, Melville C. Relapse in schizophrenia. Am J Psychiatry 1980; 137: 801–5PubMed

94.

Heinrichs DW, Carpenter WT. Prospective study of prodromal symptoms in schizophrenia relapse. Am J Psychiatry 1985; 142: 371–3PubMed

95.

Subotnik KL, Nuechterlein KH. Prodromal signs and symptoms of schizophrenic relapse. J Abnorm Psychol 1988; 97: 405–12PubMedCrossRef

96.

Birchwood M, Smith J, MacMillan F, et al. Predicting relapse in schizophrenia: the development and implementation of early signs monitoring system using patients and families as observers: a preliminary investigation. Psychol Med 1989; 19: 649–56PubMedCrossRef

97.

Tarrier N, Barrowclough C, Bamrah JS. Prodromal signs of relapse in schizophrenia. Soc Psychiatry Psychiatr Epidemiol 1991; 26: 157–61PubMed

98.

Birchwood M. Early intervention in schizophrenia: theoretical background and clinical strategies. Br J Clin Psychol 1992; 31: 257–78PubMedCrossRef

99.

McGorry PD, Yung AR, Phillips LJ. Closing in: what features predict the onset of first-episode psychosis within an ultra-high-risk group? In: Zipursky RB, Schulz SC, editors. The early stages of schizophrenia. Washington, DC: American Psychiatric Publishing Inc., 2002: 3–32

100.

Yung AR, McGorry PD, McFarlane CA, et al. Monitoring and care of young people at incipient risk of psychosis. Schizophr Bull 1996; 22: 283–303PubMedCrossRef

101.

Yung AR, Phillips LJ, McGorry PD, et al. Prediction of psychosis: a step towards indicated prevention of schizophrenia. Br J Psychiatry 1998; 172(33): 14–20

102.

McGorry PD. Preventive interventions in the prepsychotic phase: panacea, pipedreams, or Pandora’s box? Presented at Second International Conference on Early Psychosis; 2000 Apr 1; New York

103.

Miller TJ, McGlashan TH, Woods SW, et al. Symptom assessment in schizophrenic prodromal states. Psychiatr Q 1999; 70: 273–87PubMedCrossRef

104.

Miller TJ, McGlashan TH, Rosen JL, et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the structured interview for prodromal syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry 2002; 159: 863–5PubMedCrossRef

105.

McGlashan TH, Johannessen JO. Early detection and intervention with schizophrenia: rationale. Schizophr Bull 1996; 22: 201–22PubMedCrossRef

106.

McGlashan TH. Early detection and intervention with schizophrenia: research. Schizophr Bull 1996; 22: 327–46PubMedCrossRef

107.

Hass GL, Garratt LS, Sweeney JA. Delay to first antipsychotic medication in schizophrenia: impact on symptomatology and clinical course of illness. J Psychiatr Res 1998; 13 Suppl. 13: 31–4

108.

Larsen TK, Johannessen JO, Opjordsmoen S. First-episode schizophrenia with long duration of untreated psychosis. Br J Psychiatry 1998; 172Suppl. 33: 40–5

109.

Johnstone EC, MacMillan J, Crow T, et al. The Northwich Park First Episodes of Schizophrenia: III. Short-term outcome in trial entrants and trial eligible patients. Br J Psychiatry 1986; 148: 128–33PubMedCrossRef

110.

Larsen TK, McGlashan TH, Moe LC. First-episode schizophrenia: I. Early course parameters. Schizophr Bull 1996; 22: 241–56PubMedCrossRef

111.

Larsen TK, McGlashan TH, Johannessen JO, et al. First-episode schizophrenia: II. Premorbid patterns by gender. Schizophr Bull 1996; 22: 257–69PubMedCrossRef

112.

Drake RJ, Clifford JH, Akhtar S, et al. Causes and consequences of duration of untreated psychosis in schizophrenia. Br J Psychiatry 2000; 177: 511–515PubMedCrossRef

113.

Lieberman JA, Perkins D, Beiger A, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 2001; 50(11): 884–97PubMedCrossRef

114.

Falloon IRH. Early intervention for first episodes of schizophrenia: a preliminary exploration. Psychiatry 1992; 55: 4–15PubMed

115.

McGorry PD, Yung AR, Phillips LJ, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002; 59(10): 921–8PubMedCrossRef

116.

McGlashan TH, Zipursky RB, Perkins D. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis: I. Study rationale and design. Schizophr Res 2003; 61: 7–18PubMedCrossRef

117.

Woods SW, Breier A, Zipursky RB, et al. Randomized trial of olanzapine vs placebo in the symptomatic acute treatment of patients meeting criteria for the schizophrenic prodrome. Biol Psychiatry 2003; 54: 453–64PubMedCrossRef

118.

McGlashan TH, Zipursky RB, Perkins DO. Olanzapine versus PBO for the schizophrenic prodrome: one-year results [poster]. 156th American Psychiatric Association 2003 Annual Meeting; 2003 May 21; San Francisco

119.

Cornblatt B, Lencz T, Kane JM. Treatment of the schizophrenia prodrome: is it presently ethical? Schizophr Res 2001; 51(1): 31–8PubMedCrossRef

120.

McGorry PD, Yung A, Phillips L. Ethics and early intervention in psychosis: keeping up the pace and staying in step. Schizophr Res 2001; 51(1): 17–29PubMedCrossRef

121.

Larsen TK, Bechdolf A, Birchwood M. The concept of schizophrenia and phase-specific treatment: cognitive-behavioral treatment in pre-psychosis and in nonresponders. J Am Acad Psychoanal Dyn Psychiatry 2003; 31(1): 209–28PubMedCrossRef

122.

Miller TJ, Zipursky RB, Perkins DO, et al. The PRIME North America randomized double-blind clinical trial of a olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis: II. Baseline characteristics of the “prodromal” sample. Schizophr Res 2003; 61: 19–30PubMedCrossRef

123.

Preda A, Miller TJ, Rosen JL, et al. Treatment histories of patients with a syndrome putatively prodromal to schizophrenia. Psychiatr Serv 2002; 53(3): 342–4PubMedCrossRef

124.

Heinssen RK, Perkins DO, Appelbaum PS, et al. Informed consent in early psychosis research: National Institute of Mental Health workshop, November 15 2000. Schizophr Bull 2001; 27(4): 571–84PubMedCrossRef

125.

Heinimaa M, Larsen TK. Psychosis: conceptual and ethical aspects of early diagnosis and intervention. Curr Opin Psychiatry 2002; 15: 533–41PubMedCrossRef

126.

Yung AR, McGorry PD. Is pre-psychotic intervention realistic in schizophrenia and related disorders? Aust N Z J Psychiatry 1997; 31: 799–805PubMedCrossRef

127.

McGlashan TH, Miller TJ, Woods SW. Pre-onset detection and intervention research in schizophrenia psychoses: current estimates of benefit and risk. Schizophr Bull 2001; 27(4): 563–70PubMedCrossRef

128.

McGlashan TH. Psychosis treatment prior to psychosis onset: ethical issues. Schizophr Res 2001; 51(1): 47–54PubMedCrossRef

129.

Schaffner KF, McGorry PD. Preventing severe mental illnesses: new prospects and ethical challenges. Schizophr Res 2001; 51(1): 3–15PubMedCrossRef

130.

Munoz RF, Le HN, Clarke G, et al. Preventing the onset of major depression. In: Gotlib IH, Hammen CL, editors. Handbook of depression. New York: The Guilford Press, 2002: 343–59

131.

Gillham JE, Shatte AJ, Freres DR. Preventing depression: a review of cognitive-behavioral and family interventions. Appl Prev Psychol 2000; 9: 63–88CrossRef

132.

Clarke GN, Hawkins W, Murphy M, et al. Targeted prevention of unipolar depressive disorder in an at-risk sample of high school adolescents: a randomized trial of a group cognitive intervention. J Am Child Adolesc Psychiatry 1995; 34: 312–21CrossRef

133.

Clarke GN, Hornbrook MC, Lynch F, et al. A randomized trial of a group cognitive intervention for preventing depression in adolescent offspring of depressed parents. Arch Gen Psychiatry 2001; 58: 1127–34PubMedCrossRef

134.

Beardslee WR, Versage EM, Gladstone TRG. Children of affectively ill parents: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 1998; 31: 1134–41CrossRef

135.

Jaycox LH, Reivich KJ, Gilliam J, et al. Prevention of depressive symptoms in school children. Behav Res Ther 1994; 32: 801–16PubMedCrossRef

136.

Beardslee WR, Gladstone TRG. Prevention of childhood depression: recent findings and future prospects. Biol Psychiatry 2001; 49: 1101–10PubMedCrossRef

137.

Kumra S, Jacobsen LK, Lenane M, et al. Case series: spectrum of neuroleptic-induced movement disorders and extrapyramidal side effects in childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry 1998; 37(2): 221–7PubMedCrossRef

138.

Lewis R. Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability and differential sensitivity to extrapyramidal symptoms. Can J Psychiatry 1998; 43: 596–604PubMed

139.

Kelly DL, Conley RR, Love RC, et al. Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. J Child Adolesc Psychopharmacol 1998; 8: 151–9PubMedCrossRef

140.

Martin A, Landan J, Leebans P, et al. Risperidone-associated weight gain in children and adolescents: a retrospective chart review. J Child Adolesc Psychopharmacol 2000; 10: 259–68PubMedCrossRef

141.

Woods SW, Martin A, Spector SG, et al. Effects of development on olanzapine-associated adverse events. J Am Acad Child Adolesc Psychiatry 2002; 41: 1439–46PubMedCrossRef

142.

Wirshing DA, Spellberg BJ, Erhart SM, et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998; 44: 778–83PubMedCrossRef

143.

Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol 2001; 11: 25–32PubMedCrossRef

144.

Mir S, Taylor D. Atypical antipsychotics and hyperglycaemia. Int Clin Psychopharmacol 2001; 16: 63–74PubMedCrossRef

145.

DeGrazia D. Ethical issues in early-intervention clinical trials involving minors at risk for schizophrenia. Schizophr Res 2001; 51(1): 77–86PubMedCrossRef

146.

Larsen TK, Johannessen JO, Guldberg C, et al. Early intervention programs in first-episode psychosis and reduction of duration of untreated psychosis (DUP). Schizophr Res 1999; 36: 344–5

147.

Lieberman J, Jody D, Giesler S, et al. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 1993; 50: 369–76PubMedCrossRef

148.

Lieberman JA, Koreen AR, Chakos M, et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry 1996; 57Suppl. 9: 5–9PubMed

149.

DeQuardo JR. Pharmacologic treatment of first-episode schizophrenia: early intervention is key to outcome. J Clin Psychiatry 1998; 59Suppl. 19: 9–17PubMed

150.

McEvoy JP, Weiden PJ, Smith TE, et al. Expert consensus guidelines series: treatment of schizophrenia. J Clin Psychiatry 1996; 57Suppl. 12B: 1–58

151.

American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 1997; 154Suppl. 4: 1–63

152.

Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first-episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56: 241–7PubMedCrossRef

153.

McGorry PD. The detection and optimal management of early psychosis. In: Lieberman JA, Murray RM, editors. Comprehensive care of schizophrenia: a textbook of clinical management. London: Martin Dunitz, 2001: 153–166

154.

Davidson L, McGlashan TH. The varied outcomes of schizophrenia. Can J Psychiatry 1997; 42(1): 34–43PubMed

155.

Brown GW, Birley JLT. Crisis and life changes and the onset of schizophrenia. J Health Social Behav 1968; 9: 203–14CrossRef

156.

Bebbington P, Wilkins S, Jones P, et al. Life events and psychosis: initial results from the Camberwell Collaborative Psychosis Study. Br J Psychiatry 1993; 162: 72–9PubMedCrossRef

157.

Brown GW, Birley JLT, Wing JK. Influence of family life on the course of schizophrenic disorders: a replication. Br J Psychiatry 1972; 121: 241–58PubMedCrossRef

158.

Vaughn CE, Leff JP. The influence of family and social factors on the course of psychiatric illness: a comparison of schizophrenic and depressed neurotic patients. Br J Psychiatry 1976; 129: 125–37PubMedCrossRef

159.

Bebbington P, Kuipers L. The predictive utility of expressed emotion in schizophrenia: an aggregate analysis. Psychol Med 1994; 24: 707–18PubMedCrossRef

160.

Bebbington P, Kuipers L. The clinical utility of expressed emotion in schizophrenia. Acta Psychiatr Scand Suppl 1994; 382: 46–53PubMedCrossRef

161.

Falloon IRH, Boyd JL, McGill CW, et al. Family management in the prevention of exacerbations of schizophrenia. N Engl J Med 1982; 306: 1437–40PubMedCrossRef

162.

Leff J, Kuipers L, Berkowitz R, et al. A controlled trial of social intervention in the families of schizophrenia patients. Br J Psychiatry 1982; 141: 121–34PubMedCrossRef

163.

Leff J, Kuipers L, Berkowitz R, et al. A controlled trial of social intervention in the families of schizophrenia patients: two-year follow-up. Br J Psychiatry 1985; 146: 594–600PubMedCrossRef

164.

Leff JP, Vaughn CE. Expressed emotion in families: its significance for mental illness. London: Guildford, 1985

165.

Birchwood M, Spencer E, McGovern D. Schizophrenia: early warning signs. Adv Psychiatr Treatment 2000; 6: 93–101CrossRef

166.

Herz MI, Lamberti S, Mintz J. A program for relapse prevention in schizophrenia: a controlled study. Arch Gen Psychiatry 2000; 57: 277–83PubMedCrossRef

Title: Prevention of Schizophrenia
Can it Be Achieved?
Authors: Cheng Lee
Professor Thomas H. McGlashan
Scott W. Woods
Publication date: 01-03-2005
Publisher: Springer International Publishing
Published in: CNS Drugs / Issue 3/2005
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI: https://doi.org/10.2165/00023210-200519030-00002

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prevention of Schizophrenia

Can it Be Achieved?

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2005

Pregabalin

Pregabalin as Adjunctive Treatment of Partial Seizures

Pregabalin as Adjunctive Treatment of Partial Seizures

Effect of Antiepileptic Drugs on Reproductive Endocrine Function in Individuals with Epilepsy

Neurologically Presenting Wilson’s Disease

US FDA-Approved Disease-Modifying Treatments for Multiple Sclerosis